MEETING OVERVIEW | We are pleased to invite you to our satellite symposium, titled Targeting Breast Cancer Molecular Phenotypes: A Dialogue Between Community and Academic Oncologists, to be held on Thursday, December 8, 2011, at the Marriott Rivercenter in San Antonio, Texas. This is an approved open satellite event at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium.
|
 AGENDA |
|
8.00 PM
|
Welcome and introduction
Kathy D. Miller, MD
|
|
|
|
|
8.05 PM
|
Defining breast cancer molecular phenotypes
Kathy D. Miller, MD
|
|
8.15 PM
|
Treatment of luminal A and B breast cancers
8.15 PM Early-stage disease
Patient Presentation – Kristina Bowen, MD
Management Discussion –Kelly Marcom, MD
|
|
|
|
|
|
8.40 PM Metastatic disease
Patient Presentation – Lee Schwartzberg, MD
Management Discussion – Hope S. Rugo, MD
|
|
|
|
|
9.05 PM
|
Treatment of HER2-enriched breast cancers
Patient Presentation – Linda Bosserman, MD
Management Discussion – Stefan Glück, MD, PhD
|
|
|
|
|
9.30 PM
|
Treatment of basal-like breast cancer
Patient Presentation – Steven Vogl, MD
Management Discussion – Lisa Carey, MD
|
|
|
|
|
9.55 PM
|
Concluding remarks
|
|
|
Kathy D. Miller, MD
|
|
|
|
|
10.00 PM
|
Adjourn
|
|
FACULTY |
Kathy D. Miller, MD
Indiana University School of Medicine
Indianapolis, Indiana
|
Academic Faculty
|
Community Faculty
|
|
Lisa Carey, MD
University of North Carolina
Chapel Hill, North Carolina
|
Linda Bosserman, MD
Wilshire Oncology Medical Group
Rancho Cucamonga, California
|
|
Stefan Glück, MD, PhD
University of Miami
Miami, Florida
|
Kristina Bowen, MD
Georgia Cancer Specialists
Atlanta, Georgia
|
|
Kelly Marcom, MD
Duke University Medical Center
Durham, North Carolina
|
Lee Schwartzberg, MD
The West Clinic
Memphis, Tennessee
|
|
Hope S. Rugo, MD
University of California San Francisco
San Francisco, California
|
Steven Vogl, MD
Bronx, New York
|
|
TARGET AUDIENCE | This educational activity is specifically designed for medical and surgical oncologists, radiologists, and other healthcare providers interested and/or involved in the treatment of patients with breast cancer. |
LEARNING OBJECTIVES | After successful completion of this educational activity, participants should be able to:
- Discuss breast cancer tumor biology, how to identify breast cancer subtypes, and the importance of consideration of breast-cancer subtypes in treatment decision-making
- Identify the treatment options for patients with luminal cancer, including endocrine therapy, chemotherapy, novel targeted agents, and the role of gene expression assays in treatment decisions
- Describe current standards of care and recent clinical trial data on novel agents for HER2-enriched breast cancers, including therapeutic strategies to overcome resistance to standard therapies
- Compare and contrast recent clinical trial data on therapies for basal-like breast cancers, including novel chemotherapeutic and targeted strategies
|
DISCLOSURES |
Disclosure of Conflicts of Interest
prIME Oncology assesses conflicts of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
Disclosure of Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
|
AMERICANS WITH DISABILITIES ACT | Event staff will be glad to assist you with any special needs (physical, dietary, etc). Please contact Brittany Brown by December 1, 2011, at +1 678 892 1360 or brittany.brown@oncoservices.com for assistance.
|
|
|
|
|
|
REGISTRATION | Thank you for your interest in our satellite symposium titled “Targeting Breast Cancer Molecular Phenotypes: A Dialogue Between Community and Academic Oncologists” taking place on Thursday, December 8, 2011 in San Antonio, Texas.
Preregistration is now closed for this program and we are no longer accepting new registrations. Those that have preregistered will be allowed to enter the room at 7.30 PM.
Doors will open to everyone at 7.45 PM and seating will be on a first come, first served basis after this time.
We look forward to seeing you on Thursday evening and hope you are enjoying the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium! |
DATE & TIME | Thursday, December 8, 2011
7.30 PM – 8.00 PM
Registration & Dinner Buffet
8.00 PM – 10.00 PM
Symposium |
LOCATION | Marriott Rivercenter
Grand Ballroom, Salons G, H & I
3rd Floor
101 Bowie Street
San Antonio, Texas 78205
Phone: 1 210 223 1000
|
SPONSORSHIP |
This activity is sponsored by prIME Oncology.
|
CONTINUING EDUCATION | prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
prIME Oncology designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Certificates of Attendance will be provided to healthcare providers not seeking AMA credits. |
FEE INFORMATION |
There is no fee to attend this activity or to obtain continuing medical education credit. However, space is limited and seating cannot be guaranteed without preregistration. Dinner will be served.
|
|
